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Introduction: Limited prospective evidence is available to guide selection of first-line 
maintenance therapy in patients with COPD. This pre-specified analysis of the EMAX trial 
explored the efficacy and safety of dual- versus mono-bronchodilator therapy in mainte-
nance-naïve and maintenance-treated patients.
Methods: The 24-week EMAX trial evaluated lung function, symptoms (including rescue 
medication use), exacerbations, and safety with umeclidinium/vilanterol, umeclidinium, and 
salmeterol in symptomatic patients at low exacerbation risk who were not receiving inhaled 
corticosteroids. Maintenance-naïve and maintenance-treated subgroups were defined by 
maintenance bronchodilator use 30 days before screening.
Results: The analysis included 749 (31%) maintenance-naïve and 1676 (69%) maintenance- 
treated patients. For both subgroups, improvements from baseline in trough FEV1 at Week 24 
(primary endpoint) were greater with umeclidinium/vilanterol versus umeclidinium (mean differ-
ence [95% CI]; maintenance-naïve: 44 mL [1, 87]; maintenance-treated: 77 mL [50, 104]), and 
salmeterol (maintenance-naïve: 128 mL [85, 171]; maintenance-treated: 145 mL [118, 172]), and in 
rescue medication inhalations/day over 24 weeks versus umeclidinium (maintenance-naïve: −0.44 
[−0.73, −0.16]; maintenance-treated: −0.28 [−0.45, −0.12]) and salmeterol (maintenance-naïve: 
−0.37 [−0.66, −0.09]; maintenance-treated: −0.25 [−0.41, −0.08]). In maintenance-naïve patients, 
umeclidinium/vilanterol numerically improved scores at Week 24 for Transition Dyspnea Index 
versus umeclidinium (0.37 [−0.21, 0.96]) and versus salmeterol (0.47 [−0.10, 1.05]) and Evaluating 
Respiratory Symptoms–COPD versus umeclidinium (−0.26 [−1.04, 0.53]) and versus salmeterol 
(−0.58 [−1.36, 0.20]), with similar improvements seen in maintenance-treated patients. All treat-
ments were well tolerated across both subgroups.
Conclusion: Similar to maintenance-treated patients, maintenance-naïve patients receiving 
umeclidinium/vilanterol showed greater improvements in lung function and symptoms com-
pared with patients receiving umeclidinium or salmeterol. These findings provide support for 
the consideration of dual bronchodilator treatment in symptomatic maintenance-naïve 
patients with COPD.
Keywords: COPD treatment, first-line therapy, maintenance-naïve, umeclidinium/vilanterol, 
umeclidinium, salmeterol
Plain Language Summary
Why was study done?
Many patients with chronic obstructive pulmonary disease (COPD) require daily medi-
cation, known as maintenance treatment, to help achieve long-term disease control. The 
Global Initiative for Chronic Obstructive Lung Disease strategy recommends that most of 
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these patients are initially treated with one long-term bronchodi-
lator medication, and are prescribed a second bronchodilator if 
their symptoms persist or worsen. However, initiating treatment 
with two bronchodilators may be appropriate for symptomatic 
patients with COPD, and may lead to better outcomes.
What did researchers do/find?
We analyzed data from a clinical trial (EMAX) that com-
pared the relative benefits of a combination of two bronchodila-
tors, umeclidinium/vilanterol (UMEC/VI), with a single 
bronchodilator (either UMEC or salmeterol [SAL]) over 6 
months. In this analysis, we looked specifically at patients who 
had not been receiving any other maintenance treatment for 
COPD in the month before enrollment in the trial (maintenance- 
naïve), and patients who had received maintenance treatment in 
the month before the trial (maintenance-treated). We found that 
maintenance-naïve and maintenance-treated patients receiving 
UMEC/VI had better lung function and improved symptoms, 
were less dependent on their reliever inhaler, and were less likely 
to experience disease worsening than patients receiving UMEC 
or SAL.
What do these results mean?
A combination of two bronchodilators, such as UMEC/VI, 
may be better than a single bronchodilator for treating sympto-
matic patients with COPD, whether or not they have previously 
received maintenance treatment. Physicians should consider pre-
scribing a combination of two bronchodilators as initial treatment 
for patients with significant symptom burden who have not pre-
viously received long-term maintenance treatment for COPD.
Introduction
Many patients with chronic obstructive pulmonary disease 
(COPD) remain symptomatic while on one long-acting 
bronchodilator.1 It is well established that COPD symp-
toms have a detrimental impact on health status and qual-
ity of life, with many symptomatic patients also 
experiencing anxiety and/or depression.2,3 Furthermore, 
symptomatic patients are at increased risk of exacerbations 
and have poorer disease prognosis than those with well- 
controlled symptoms.4,5
Meta-analyses of clinical trial data have shown that dual 
long-acting muscarinic antagonist (LAMA)/long-acting β2- 
agonist (LABA) combination therapies provide greater 
improvements in lung function, symptoms, and health-related 
quality of life, as well as a reduced risk of exacerbations 
compared with LAMA or LABA monotherapy.6–9 
Furthermore, dual LAMA/LABA therapies have a similar 
safety profile to LAMA or LABA monotherapies, with no 
apparent increase in the incidence of serious adverse events 
(SAEs).7 As such, dual long-acting bronchodilators may be an 
appropriate option for initial maintenance therapy in sympto-
matic patients. In recognition of this, the American Thoracic 
Society has made a strong recommendation for the use of 
LAMA/LABA combination therapy over LAMA or LABA 
monotherapy in patients with COPD and dyspnea or exercise 
intolerance.10 In addition, some national guidelines, including 
those provided by the UK National Institute for Health and 
Care Excellence, recommend dual bronchodilator treatment as 
first-line therapy in certain patients, such as those without 
features suggesting steroid responsiveness or asthma, who 
remain breathless or experience exacerbations despite use of 
short-acting bronchodilators.11 In contrast, for patients with 
symptomatic COPD and low risk of exacerbations the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) 
recommends initial maintenance treatment with LAMA or 
LABA monotherapy, or LAMA/LABA dual therapy for 
those with severe breathlessness.12 Current recommendations 
for first-line LAMA/LABA use are therefore inconsistent, and 
have been formulated based on limited evidence from clinical 
trials in patients already receiving maintenance therapy, often 
combination treatments, and usually in the absence of any 
prospective data on the efficacy of dual bronchodilators as first- 
line maintenance therapy. Available evidence to guide clini-
cians in their choice of first-line therapy for patients with 
COPD is therefore limited.
Previous studies suggest that a considerable population of 
patients have a significant symptom burden and exacerbation 
risk and yet do not receive regular maintenance therapy and 
remain maintenance-naïve (MN).13–15 Post hoc evidence in 
MN patients indicates that dual bronchodilator therapy may 
have larger beneficial effects on lung function, symptoms, 
health status, rescue medication use, and COPD stability com-
pared with monotherapy.13,15–17 Early initiation of LAMA/ 
LABA therapy may therefore improve outcomes for sympto-
matic patients with COPD; however, prospective studies are 
required to corroborate this.
The Early MAXimization of bronchodilation for 
improving COPD stability (EMAX) trial investigated the 
efficacy and safety of umeclidinium/vilanterol (UMEC/VI; 
LAMA/LABA), umeclidinium (UMEC; LAMA), and sal-
meterol (SAL; LABA) in symptomatic patients with 
COPD at low risk of exacerbation who were not receiving 
inhaled corticosteroids (ICS).18 In this pre-specified sub-
group analysis, clinical benefits and safety of UMEC/VI 
compared with UMEC and SAL were evaluated in MN 
patients and in patients who were receiving maintenance 
treatment prior to the start of the study (maintenance- 
treated [MT] patients). A secondary aim of this analysis 
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was to observe the mean improvements from baseline with 
UMEC/VI, UMEC, or SAL in MN and MT patients.
Materials and Methods
Study Design
The multicenter, double-blind, double-dummy, 3-arm paral-
lel-group EMAX trial randomized patients 1:1:1 to 24 weeks 
of UMEC/VI (62.5/25 µg) once daily via the ELLIPTA 
inhaler, UMEC (62.5 µg) once daily via ELLIPTA, or 
SAL (50 µg) twice-daily via the DISKUS inhaler. The trial 
was conducted between June 2017 and June 2018, and full 
details of the study design have been published previously.18
This study was performed according to the Declaration 
of Helsinki and received appropriate ethical approval 
(Supplementary Table S1). All patients provided written 
informed consent via a form signed at either the Pre- 
screening or Screening visit.
Patients
Eligible patients were ≥40 years of age and were current or 
former smokers with a diagnosis of COPD, pre- and post- 
albuterol forced expiratory volume in 1 second/forced vital 
capacity (FEV1/FVC) ratio <0.7, post-albuterol FEV1 of 
≥30–≤80% predicted (corresponding to GOLD grade 2 or 3), 
COPD Assessment Test (CAT) score ≥10, and ≤1 moderate 
and no severe exacerbations in the previous year. Prior to 
screening and during the 4-week run-in period, treatment 
with ≤1 maintenance bronchodilator monotherapy (LAMA 
or LABA) was permitted, with all eligible patients continuing 
to be symptomatic (CAT score ≥10) on their run-in treatments. 
Patients had no ICS or ICS/LABA treatment for ≥6 weeks 
prior to run-in, and no LAMA/LABA combination therapy for 
≥2 weeks prior to run-in. After the run-in period, study treat-
ment was given for 24 weeks.
For this analysis, MN and MT subgroups were defined 
by maintenance bronchodilator use during the period from 
30 days prior to screening until the first dose of study 
treatment. Over this period, MN patients did not receive 
any COPD maintenance medications except for short- 
acting bronchodilators as rescue medication.
Endpoints
This secondary analysis of the EMAX trial included spirome-
try, patient-reported outcomes (PROs), exacerbations, short- 
term disease stability (clinically important deteriorations 
[CID]), and safety outcomes. Spirometry assessments com-
prised change from baseline in trough FEV1, FVC, and 
inspiratory capacity (IC). PROs comprised change from base-
line for self-administered computerized Transition Dyspnea 
Index (SAC-TDI) focal score, Evaluating Respiratory 
Symptoms–COPD (E-RS) total score, rescue medication use 
(including inhalations/day and the proportion of rescue-free 
days), global assessment of disease severity (GADS), St 
George’s Respiratory Questionnaire (SGRQ) total score, and 
CAT total score. Response rates were calculated based on the 
proportion of individual patients with a ≥1-unit improvement 
in SAC-TDI score, ≥2-point reduction in E-RS score from 
baseline, ≥4-point reduction in SGRQ score from baseline, 
and ≥2-unit improvement in CAT score from baseline. Short- 
term disease worsening outcomes included time to first mod-
erate/severe exacerbation and risk of a first CID. For individual 
patients, risk of a first CID was assessed using three different 
composite definitions. Definition 1 comprised a first moderate 
or severe exacerbation, and/or a decrease in trough FEV1 from 
baseline of ≥100 mL, and/or a deterioration in health status 
indicated by an increase in SGRQ score from baseline of ≥4 
units. Definition 2 was similar to Definition 1, except that 
a CAT deterioration (≥2 units from baseline) replaced the 
SGRQ deterioration. Definition 3 comprised a first moderate 
or severe exacerbation, and/or a SGRQ deterioration, and/or 
a CAT deterioration, and/or a SAC-TDI deterioration indicated 
by a decrease of ≥1 unit. Safety was assessed based on the 
incidence of adverse events (AEs) and SAEs.
Statistical Analysis
The EMAX trial was powered to detect differences between 
treatments for trough FEV1 and SAC-TDI at Week 24 in the 
intent-to-treat (ITT) population; however, the trial was not 
powered to detect treatment differences in the smaller main-
tenance treatment subgroups. For this reason, treatment differ-
ences with 95% confidence intervals (CI) are described 
without reference to statistical significance within subgroups, 
although P-values are presented in the figures and tables.
Full details of the statistical analyses have been 
reported previously.18 Comparisons of change from base-
line in lung function and PROs used mixed model repeated 
measures (MMRM) analyses. Least squares (LS) mean 
and LS mean change from baseline with estimated treat-
ment differences are reported with 95% CIs. Response 
rates were compared using generalized linear mixed 
model analyses, and odds ratios (OR) with 95% CIs are 
reported. For time to first CID, hazard ratios (HR) and 
95% CIs were calculated using a Cox proportional hazards 
model. A full description of the covariates included in 
each model is included in the Supplementary Methods.
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To assess improvements from baseline with UMEC/VI, 
UMEC, and SAL in MN and MT patients, multidimen-
sional plots of LS mean change from baseline in the four 
clinical outcomes of interest (trough FEV1 at Week 24 
[upward axis], SAC-TDI focal score at Week 24 [right-
ward axis], rescue medication mean inhalations/day over 
Weeks 1–24 [downward axis], and SGRQ score at Week 
24 [leftward axis]) are presented for each subgroup.
Safety endpoints were analyzed descriptively.
Results
Study Population
The ITT population included 2425 patients, of whom 749 
(31%) were MN (UMEC/VI: 250, UMEC: 250, SAL: 249) 
and 1676 (69%) were MT (UMEC/VI: 562, UMEC: 554, 
SAL: 560). Overall, 619 (83%) MN patients and 1431 
(85%) MT patients completed study treatment. In the 
MN subgroup, 84%, 80%, and 84% of patients receiving 
UMEC/VI, UMEC, and SAL completed the trial; the cor-
responding proportions in the MT subgroup were 90%, 
81%, and 85%. A post hoc analysis revealed that the risk 
of early withdrawal in the MT subgroup was lower with 
UMEC/VI than with UMEC (risk reduction [95% CI]: 
48% [28, 62]) or SAL (36% [10, 54]). In the MN sub-
group, the difference in risk of early withdrawal was 24% 
(−15, 50) with UMEC/VI versus UMEC and 5% (−47, 39) 
versus SAL.
Baseline demographics and clinical characteristics for 
each subgroup are described in Table 1 and were well 
balanced between treatment arms (Supplementary Table 
S2). Compared with the MT subgroup, the MN subgroup 
was slightly younger and included a greater proportion of 
Table 1 Baseline Demographics and Clinical Characteristics
ITT (N=2425) MN (N=749) MT (N=1676)
Age, years, mean (SD) 64.6 (8.5) 63.0 (8.3) 65.4 (8.4)
Female, n (%) 988 (41) 343 (46) 645 (38)
Current smoker, n (%) 1203 (50) 493 (66) 710 (42)
Smoking pack-years, mean (SD) 48.4 (26.5) 49.9 (25.2) 47.7 (27.0)
Duration of COPD, years, mean (SD) 8.3 (6.6) 8.3 (6.8) 8.3 (6.5)
Moderate COPD exacerbation in past 12 monthsa, n (%) 393 (16) 77 (10) 316 (19)
Post-albuterol percent predicted FEV1, mean (SD) 55.4 (12.7) 57.0 (12.3) 54.7 (12.9)
Post-albuterol FEV1/FVC, mean (SD) 0.52 (0.10) 0.54 (0.10) 0.51 (0.10)
Percent reversibility to albuterol, mean (SD) 10.5 (13.1) 12.8 (12.8) 9.4 (13.1)
GOLD gradeb, n (%)
2 1569 (65) 526 (70) 1043 (62)
3 851 (35) 222 (30) 629 (38)
Baseline FEV1, mL, mean (SD) 1491 (517) 1541 (531) 1468 (509)
BDI focal score, mean (SD) 7.0 (1.9) 7.1 (2.0) 7.0 (1.8)
E-RS total score, mean (SD) 10.6 (5.7) 11.6 (6.0) 10.2 (5.5)
SGRQ score, mean (SD) 44.7 (16.2) 48.1 (17.2) 43.2 (15.5)
CAT score, mean (SD) 19.2 (6.1) 21.1 (6.5) 18.4 (5.7)
Rescue medication usec, puffs/day, mean (SD) 2.2 (2.5) 2.8 (3.0) 1.9 (2.1)
Rescue-free daysc, % (SD) 39.4 (41.6) 35.6 (41.4) 41.0 (41.6)
Notes: aNumber of patients with an exacerbation requiring oral or systemic corticosteroids and/or antibiotics (moderate) in 12 months prior to screening (patients with >1 
moderate exacerbation or with a severe exacerbation [requiring hospitalization] were excluded from the study); ban additional 4 (<1%) patients with GOLD grade 1 (MN 
n=1; MT n=3) were randomized; cduring the 4-week run-in period. 
Abbreviations: BDI, baseline dyspnea index; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms–COPD; 
FEV1; forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; MN, maintenance- 
naïve; MT, maintenance-treated; SD, standard deviation; SGRQ, St George’s Respiratory Questionnaire.
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females and current smokers. The MN subgroup appeared 
to have better lung function on average than the MT 
subgroup, as indicated by a higher mean FEV1 and 
a larger proportion of individuals who were classified as 
GOLD grade 2 versus 3. Furthermore, the MN subgroup 
had more severe symptom burden and worse health status 
(as indicated by higher mean CAT, E-RS, and SGRQ 
scores), as well as greater mean daily albuterol use than 
the MT subgroup. Fewer MN than MT patients had 
a moderate exacerbation in the previous year.
Lung Function Outcomes
In MN patients, mean (95% CI) change from baseline in 
trough FEV1 at Week 24 was 44 mL (1, 87) and 128 mL 
(85, 171) greater with UMEC/VI versus UMEC and SAL, 
respectively (Table 2; Figure 1). Mean change from base-
line in trough FVC and trough IC at Week 24 were also 
generally greater with UMEC/VI versus UMEC and SAL 
in MN patients (Table 2).
In MT patients, mean (95% CI) change from baseline 
in trough FEV1 at Week 24 was 77 mL (50, 104) and 
145 mL (118, 172) greater with UMEC/VI versus UMEC 
and SAL, respectively (Table 2; Figure 1). Mean changes 
from baseline in trough FVC and trough IC at Week 24 
were also greater with UMEC/VI versus UMEC and SAL 
(Table 2).
In both MN and MT subgroups, mean changes from 
baseline in trough FEV1, and trough FVC at Week 24 were 
greater with UMEC versus SAL (Supplementary 
Table S3).
Symptom Severity and Health Status 
Outcomes
In the MN subgroup, mean improvements from baseline in 
SAC-TDI focal score and E-RS total score at all time points 
(Figure 2A–B) and the odds of responding for either outcome 
(Figure 3A) were greater with UMEC/VI versus UMEC or 
SAL. Mean improvements in rescue medication inhalations/ 
day and the proportion of rescue-free days were also greater 
with UMEC/VI versus both monotherapies at all time points 
(Figure 4A–B) and over Weeks 1–24 (Table 2). A higher 
proportion of patients receiving UMEC/VI reported GADS 
to be improved by Week 24 (68%) compared with UMEC 
(65%) and SAL (63%) (Table 2).
For SGRQ and CAT score, treatment differences favoring 
UMEC/VI were not consistently seen across all time points, 
although mean improvements from baseline in CAT score at 
Week 24 were numerically greater with UMEC/VI compared 
with monotherapy (Figure 5A–B). The odds of responding 
for either outcome were similar with UMEC/VI and UMEC, 
but were greater with UMEC/VI versus SAL (Figure 3A).
For MT patients, mean improvements from baseline in 
SAC-TDI focal score and E-RS total score were greater with 
UMEC/VI versus UMEC or SAL at all time points (Figure 
6A–B), and the odds of responding for each outcome were 
greater with UMEC/VI compared with UMEC or SAL 
(Figure 3B). Mean improvements from baseline in the per-
centage of rescue-free days were greater with UMEC/VI 
versus monotherapy at all time points, although this was 
less clear for mean rescue medication inhalations/day 
(Figure 7A–B); mean change from baseline for both end-
points over Weeks 1–24 was greater with UMEC/VI versus 
UMEC or SAL (Table 2). A greater proportion of patients 
reported the overall severity of their COPD (GADS) 
improved from baseline to Week 24 with UMEC/VI (66%) 
versus UMEC (60%) and SAL (61%) (Table 2).
Mean improvements from baseline in SGRQ and CAT 
scores were consistently greater with UMEC/VI over SAL, 
but not UMEC, at all time points (Figure 8A–B). The odds of 
being a responder for either SGRQ or CAT were numerically 
greater with UMEC/VI than with UMEC or SAL (Figure 3B).
For both subgroups, SAC-TDI scores at Week 24 were 
similar with UMEC and SAL; mean improvements from 
baseline in E-RS total score at Weeks 21–24 were slightly 
greater with UMEC versus SAL (Supplementary Table S3). 
Improvements from baseline in rescue medication use were 
generally similar with UMEC and SAL, although improve-
ment from baseline in the percentage of rescue-free days was 
slightly larger with SAL than UMEC in the MN subgroup 
(Supplementary Table S3). In both subgroups, a similar pro-
portion of patients reported improvement in the overall 
severity of their COPD from baseline to Week 24 with 
UMEC compared with SAL (Supplementary Table S3).
Exacerbations and Disease Stability 
Outcomes
In the MN subgroup, the risk of a first moderate/severe exacer-
bation with UMEC/VI was similar versus UMEC, with a risk 
reduction of 8% (HR: 0.92; 95% CI: −68, 49), and lower versus 
SAL with a risk reduction of 42% (HR: 0.58; 95% CI: 0, 66). 
There was a reduced risk of a first CID with UMEC/VI versus 
UMEC for two of the three CID definitions, and versus SAL 
for all three definitions (Figure 9A).
International Journal of Chronic Obstructive Pulmonary Disease 2021:16                                                https://doi.org/10.2147/COPD.S291751                                                                                                                                                                                                                       
DovePress                                                                                                                       
1943
Dovepress                                                                                                                                                         Bjermer et al

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































https://doi.org/10.2147/COPD.S291751                                                                                                                                                                                                                               
DovePress                                                                                              
International Journal of Chronic Obstructive Pulmonary Disease 2021:16 1944
Bjermer et al                                                                                                                                                         Dovepress















































































In MT patients, the risk of a first moderate/severe 
exacerbation was reduced by 22% with UMEC/VI versus 
UMEC (HR: 0.78; 95% CI: −5, 42) and 33% versus SAL 
(HR: 0.67; 95% CI: 11, 50). The risk of a first CID was 
reduced with UMEC/VI versus UMEC and versus SAL for 
all three CID definitions (Figure 9B).
Effect of Maintenance Therapy Status on 
Mean Improvements from Baseline
The overall impact of each treatment was evaluated using 
multidimensional plots of the four clinical outcomes of interest 
(trough FEV1 at Week 24 [upward axis], SAC-TDI focal score 
at Week 24 [rightward axis], rescue medication mean inhala-
tions/day over Weeks 1–24 [downward axis], and SGRQ score 
at Week 24 [leftward axis]). For both MN (Figure 10A) and 
MT (Figure 10B) subgroups, greater LS mean changes from 
baseline were observed with UMEC/VI compared with 
UMEC and SAL for all outcomes except SGRQ. For both 
subgroups, a greater total area inside the plots was seen for 
UMEC/VI versus either monotherapy, indicating greater ben-
efits across the assessed clinical outcomes. For all four end-
points, improvements from baseline were numerically greater 
in the MN subgroup than in the MT subgroup for all treatment 
arms. For improvements from baseline in trough FEV1 and 
rescue medication use, there was no overlap in CIs between 
the MN and MT subgroups for either outcome in any treatment 
arm, suggesting consistently greater improvements for MN 
versus MT patients irrespective of treatment (Figure 10). 
A similar pattern of improvements from baseline was 
observed when these outcomes were assessed at Week 4 for 
MN and MT patients (Supplementary Figure S1). Absolute 
mean values at Week 24 (or over Weeks 1–24 for rescue 
medication use) for all four measures were similar between 
the MN and MT subgroups (Supplementary Figure S2).
Safety
The incidence of patients reporting on-treatment AEs and 
SAEs was similar in all treatment arms in both subgroups 
(Table 3). In the MN subgroup, no SAEs were considered 
drug-related and no fatal SAEs were reported. In the MT 
subgroup, eight fatal SAEs were reported (four each in the 
UMEC/VI and UMEC treatment arms); however, no fatal 
or non-fatal SAEs were considered related to the study 
medication. As expected based on the known safety profile 
of long-acting bronchodilators, and consistent with the ITT 
population,18 the most common AE was nasopharyngitis 
in both subgroups (Table 3).
Discussion
This pre-specified analysis of the EMAX trial by patient main-
tenance therapy status prior to randomization found larger 
Figure 1 Change from baseline in trough FEV1 at Weeks 4, 12, and 24 in (A) MN 
and (B) MT patients. 
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 
1 second; LS, least squares; MN, maintenance-naïve; MT, maintenance-treated; 
SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol.
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Figure 2 MN patients: (A) SAC-TDI focal score and (B) change from baseline in E-RS total score. 
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms-COPD; LS, least squares; MN, maintenance- 
naïve; MT, maintenance-treated; SAC-TDI, self-administered computerized Transition Dyspnea Index; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol.
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Figure 3 Proportion of responders for symptoms (SAC-TDI focal score, E-RS total score) and health status outcomes (SGRQ, and CAT) in (A) MN and (B) MT patients. 
Abbreviations: CAT, COPD Assessment Test; CI, confidence interval; COPD, chronic obstructive pulmonary disease; E-RS, Evaluating Respiratory Symptoms–COPD; MN, 
maintenance-naïve; MT, maintenance-treated; n/N number of responders/number of patients with analyzable data; SAC-TDI, self-administered computerized Transition 
Dyspnea Index; SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
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Figure 4 MN patients: change from baseline in (A) percentage of rescue-free days and (B) rescue medication inhalations/day. 
Abbreviations: CI, confidence interval; LS, least squares; MN, maintenance-naïve; MT, maintenance-treated; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol.
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improvements in lung function and reductions in rescue med-
ication use, which may be an indirect marker of reduced 
symptom burden, in patients receiving UMEC/VI compared 
with either monotherapy from Week 4 to Week 24, in both the 
MN and MT subgroups. Rescue medication benefits of 
UMEC/VI included both a reduced number of uses per day 
and increased rescue-free days versus UMEC and SAL, sug-
gesting that patients’ symptoms improved as they were less 
dependent on their rescue inhaler.19 For SAC-TDI and E-RS at 
Week 24, UMEC/VI also showed numerically larger improve-
ments from baseline versus monotherapy. In addition, risk of 
exacerbations and risk of CID were generally reduced with 
UMEC/VI versus monotherapy for both subgroups. Patients in 
both subgroups also showed generally greater improvements 
with UMEC versus SAL for lung function (trough FEV1, 
Figure 5 MN patients: change from baseline in (A) SGRQ total score and (B) CAT 
score. 
Abbreviations: CAT, COPD Assessment Test; CI, confidence interval; COPD, 
chronic obstructive pulmonary disease; LS, least squares; MN, maintenance-naïve; 
MT, maintenance-treated; SAL, salmeterol; SGRQ, St George’s Respiratory 
Questionnaire; UMEC, umeclidinium; VI, vilanterol.
Figure 6 MT patients: (A) SAC-TDI focal score and (B) change from baseline in 
E-RS total score. 
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary 
disease; E-RS, Evaluating Respiratory Symptoms-COPD; LS, least squares; MN, 
maintenance-naïve; MT, maintenance-treated; SAC-TDI, self-administered compu-
terized Transition Dyspnea Index; SAL, salmeterol; UMEC, umeclidinium; VI, 
vilanterol.
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trough FVC, and trough IC), but not for symptoms outcomes 
(SAC-TDI, E-RS, and rescue medication use) or COPD sever-
ity (GADS). All treatments were equally well tolerated in both 
subgroups. Taken together, these data support an incremental 
efficacy benefit on lung function, rescue medication use and 
greater disease stability when using dual bronchodilator treat-
ment as initial maintenance therapy.
In the GOLD strategy report, maintenance bronchodilator 
therapy is recommended for patients with symptomatic 
COPD,12 yet 31% of patients in this study were MN. This is 
consistent with prior estimates of the proportion of patients 
with COPD who do not receive any maintenance treatment 
despite being symptomatic.14 The lack of previous 
Figure 7 MT patients: change from baseline in (A) percentage of rescue-free days 
and (B) rescue medication inhalations/day. 
Abbreviations: CI, confidence interval; LS, least squares; MN, maintenance-naïve; 
MT, maintenance-treated; SAL, salmeterol; UMEC, umeclidinium; VI, vilanterol.
Figure 8 MT patients: change from baseline in (A) SGRQ total score and (B) CAT score. 
Abbreviations: CAT, COPD Assessment Test; CI, confidence interval; COPD, 
chronic obstructive pulmonary disease; LS, least squares; MN, maintenance-naïve; 
MT, maintenance-treated; SAL, salmeterol; SGRQ, St George’s Respiratory 
Questionnaire; UMEC, umeclidinium; VI, vilanterol.
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maintenance treatment suggests that the symptoms of these 
patients had been neglected and not treated appropriately, as 
these patients had been diagnosed with COPD for the same 
length of time as the MT patients, and had similar CAT scores. 
One potential reason for this could be that patients do not seek 
appropriate assessment and maintenance treatment due to 
a disparity between patient perceived and actual COPD 
severity.5 Furthermore, a greater proportion of MN than MT 
patients were current smokers; in the former group, it is possi-
ble that COPD symptoms such as dyspnea have been misat-
tributed to smoking, further contributing to underdiagnosis and 
undertreatment.20,21 This highlights the importance of thor-
ough assessment and treatment (including smoking cessation) 
in MN patients with COPD symptoms, to prevent further 
deterioration.12
A secondary objective of this analysis of the EMAX trial 
was to explore whether MN patients demonstrated greater 
improvements from baseline with dual- or mono- 
bronchodilator therapy compared with MT patients. There 
was a consistent trend for greater mean improvements from 
baseline in MN versus MT patients across all three treatment 
regimens for FEV1, SAC-TDI, rescue medication use, and 
SGRQ. This suggests that MN patients, who were receiving 
no maintenance treatment at the start of the trial, gained greater 
benefit from bronchodilator therapy than MT patients, who 
were already receiving bronchodilator therapy. MN patients 
had a greater mean rescue medication use at baseline compared 
with the MT subgroup, indicating that these patients were 
dependent on short-acting bronchodilators to control their 
COPD symptoms in the absence of adequate maintenance 
treatment.22,23 Accordingly, the MN subgroup had more severe 
symptom burden and worse health status at baseline (as indi-
cated by E-RS, CAT, and SGRQ scores), but both subgroups 
had a similar mean lung function, symptoms, and health status 
at the end of the study. These numerically larger mean 
improvements from baseline in the MN versus MT subgroup 
suggest a significant unmet need for effective maintenance 
Figure 9 Risk of a first clinically important deterioration in (A) MN and (B) MT patients. an/N, number of patients with an event/number of patients with at least 1 post 
baseline assessment (not including exacerbations) for at least one of the individual components or patients who had an exacerbation; bmoderate/severe exacerbation. 
Abbreviations: CAT, COPD Assessment Test; CI, confidence interval; CID, clinically important deterioration; COPD, chronic obstructive pulmonary disease; FEV1 trough 
forced expiratory volume in 1 s; HR, hazard ratio; MN, maintenance-naïve; MT, maintenance-treated; SAC-TDI, self-administered computerized Transition Dyspnea Index; 
SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
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Figure 10 LS mean change from baseline in trough FEV1 at Week 24, SAC-TDI focal score at Week 24, rescue medication inhalations/day over Weeks 1–24, and SGRQ 
score at Week 24 with UMEC/VI, UMEC, and SAL in (A) MN and (B) MT patients. All values are LS mean (95% CI). Negative changes from baseline are not shown, so 
a change from baseline in trough FEV1 at Week 24 of −56 mL with SAL in the MT subgroup is presented as zero. *P<0.05 vs UMEC and †vs SAL. 
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; LS, least squares; MN, maintenance-naïve; MT, maintenance-treated; SAC-TDI, self- 
administered computerized Transition Dyspnea Index; SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.
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treatment among this population. However, it should be noted 
that in the responder analyses for SAC-TDI, E-RS, SGRQ, and 
CAT, point estimates for the odds of responding were generally 
higher in MT then in MN patients. Furthermore, comparisons 
between the MN and MT subgroups should be made with 
caution, since the study was not powered for this analysis and 
there were potentially confounding differences between the 
subgroups at baseline. For example, a previous analysis of 
the EMAX trial has indicated that high SABA use may be 
a confounding factor when analyzing symptomatic treatment 
benefits between maintenance bronchodilators.19
The findings of this prospective analysis are generally 
consistent with previous post hoc analyses. A pooled analysis 
of 1056 MN patients from two randomized controlled trials 
found statistically significant improvements in lung function 
and symptoms with the LAMA/LABA combination 
aclidinium bromide/formoterol fumarate compared with its 
monocomponents.15 Another pooled analysis of 533 MN 
patients showed a significant improvement in trough FEV1 
with UMEC/VI versus tiotropium that was numerically larger 
in the MN subgroup (146 mL) than in the ITT population 
(95 mL), as well as significant improvements in rescue medi-
cation use and CID risk.13 In a subgroup analysis of 678 MN 
patients in the OTEMTO studies (powered to detect changes in 
the primary outcomes of SGRQ score and FEV1), greater 
improvements in lung function, SGRQ score, and TDI score 
were seen with tiotropium/olodaterol versus tiotropium mono-
therapy in MN patients.16 Furthermore, a pooled analysis of the 
Phase III PINNACLE studies showed significant lung function 
improvements with glycopyrrolate/formoterol fumarate versus 
its monocomponents in MN patients.17 Overall, the available 
data, including the results of this analysis, indicate that dual 



















AE 94 (38) 96 (38) 101 (41) 291 (39) 221 (39) 220 (40) 213 (38) 654 (39)
Drug-related AE 9 (4) 12 (5) 12 (5) 33 (4) 20 (4) 25 (5) 15 (3) 60 (4)
AE leading to study 
withdrawal
11 (4) 10 (4) 9 (4) 30 (4) 21 (4) 26 (5) 17 (3) 64 (4)
SAE, n (%)
Non-fatal SAE 12 (5) 15 (6) 13 (5) 40 (5) 34 (6) 16 (3) 25 (4) 75 (4)
Fatal SAEa 0 0 0 0 4 (<1) 4 (<1) 0 8 (<1)
Drug-related SAE 0 0 0 0 0 0 0 0
AEs occurring in >2% of patients on any treatment, n (%)
Nasopharyngitis 14 (6) 15 (6) 19 (8) 48 (6) 54 (10) 72 (13) 65 (12) 191 (11)
URTI 10 (4) 8 (3) 9 (4) 27 (4) 9 (2) 4 (<1) 11 (2) 24 (1)
Influenza 6 (2) 2 (<1) 8 (3) 16 (2) 14 (2) 7 (1) 10 (2) 31 (2)
Back pain 3 (1) 6 (2) 5 (2) 14 (2) 7 (1) 7 (1) 10 (2) 24 (1)
Cough 3 (1) 5 (2) 3 (1) 11 (1) 11 (2) 6 (1) 7 (1) 24 (1)
Oropharyngeal pain 2 (<1) 6 (2) 3 (1) 11 (1) - - - -
Nausea 1 (<1) 7 (3) 3 (1) 11 (1) - - - -
UTI 4 (2) 3 (1) 4 (2) 11 (1) - - - -
Sinusitis 2 (<1) 3 (1) 5 (2) 10 (1) - - - -
Headache 2 (<1) 5 (2) 2 (<1) 9 (1) 8 (1) 12 (2) 4 (<1) 24 (1)
Hypertension 3 (1) 4 (2) 2 (<1) 9 (1)
Muscle spasms 2 (<1) 0 4 (2) 6 (<1) - - - -
Bronchitis - - - - 8 (1) 8 (1) 10 (2) 26 (2)
Pneumonia - - - - 6 (1) 9 (2) 6 (1) 21 (1)
Notes: aFor the MT subgroup, consistent with previous studies, the incidence of fatal cardiovascular SAEs was <1% in all treatment groups, with three cardiac disorders 
observed in the UMEC/VI arm and one in the UMEC arm (one acute myocardial infarction in each treatment group). No fatal cardiovascular SAEs were observed in the MN 
subgroup. 
Abbreviations: AE, adverse event; MN, maintenance-naïve; MT, maintenance-treated; SAE, serious adverse event; SAL, salmeterol; UMEC, umeclidinium; URTI, upper 
respiratory tract infection; UTI, urinary tract infection; VI, vilanterol.
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bronchodilator therapy provides incremental benefits with 
regard to lung function and symptoms when used as initial 
maintenance therapy.
A key strength of this study was the prospective, well- 
balanced randomization of a well-characterized MN popu-
lation. Patients in both subgroups were not receiving con-
current ICS, which can influence the efficacy of add-on 
therapy, particularly LABA, in patients with COPD.22,24 
Certain study limitations should be considered; most 
importantly, the MN population represented only 31% of 
the overall study population and the study was not pow-
ered to detect treatment differences in the MN or MT 
subgroups. This is reflected in the inconsistency of the 
CID results, as in the MN population the reduction in 
risk of a CID favored UMEC/VI versus UMEC in two of 
the three definitions of a CID. A greater proportion of 
patients receiving monotherapy withdrew from the trial 
compared with patients receiving UMEC/VI, particularly 
in the UMEC arm, which may have reduced the observed 
treatment differences between dual and monotherapy due 
to a “healthy survivor” effect.25 UMEC/VI was compared 
with SAL rather than VI (the LABA component of 
UMEC/VI) in this post-registration trial because VI was 
not licensed as a monotherapy in any country. However, an 
indirect treatment comparison has suggested that SAL and 
VI are likely to have broadly similar effects on trough 
FEV1 and PROs including TDI.26 Additional studies that 
are powered to detect treatment differences for lung func-
tion and symptoms outcomes in MN patients are needed to 
further evaluate the benefits of initial maintenance therapy 
with dual versus mono bronchodilator initial maintenance 
therapy in symptomatic patients with COPD at low risk of 
exacerbations.
Conclusions
In this pre-specified subgroup analysis of patients with COPD 
in the EMAX trial, UMEC/VI provided clinically important 
additional improvements in lung function and symptoms and 
was well tolerated compared with UMEC and SAL monother-
apy in MN patients, as well as in MT patients. There was an 
expected trend for greater improvement from baseline in lung 
function and rescue medication use in MN patients than in MT 
patients, for all treatments. Despite the small sample size in 
each subgroup, these findings provide support for the consid-
eration of dual bronchodilator treatment early in symptomatic 
maintenance-naïve patients with COPD.
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